At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115, ...

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating on the shares. The company recently announced plans to ...

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...